Product Development Program Update and New Investor Presentation

Melbourne, Australia, 26 June 2018: Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX: CYP) is pleased to announce an update to its product development activities and a new investor presentation to be presented at a series of upcoming institutional investor meetings.

Key Highlights

- **CYP-001 GvHD program positioned to progress to Phase 2 development** following compelling Phase 1 clinical data released last week; GvHD indication currently partnered with Fujifilm
- Cynata selects cardiovascular disease as a high-priority target area following a comprehensive review of MSC landscape conducted with ClearView Healthcare Partners
  - Cardiovascular disease is the leading cause of premature death worldwide¹, complications of which include critical limb ischemia, diabetic ulcers and heart disease
- **Cynata will proceed with Phase 2 clinical programme in critical limb ischemia** and continue to work with its partners to progress other cardiovascular disease indications
  - Critical limb ischemia represents ~US$1.4billion/year commercial opportunity for novel MSC therapies
- **Cynata well-funded to progress its clinical programme**, following $5.2 million placement of shares to leading institutional investor Fidelity International on 30-May-18

An updated investor presentation providing an overview of Cynata’s corporate and clinical strategy accompanies this release.

Dr Ross Macdonald, Chief Executive Officer of Cynata said: “After reporting excellent safety and efficacy data from our Phase 1 clinical trial of CYP-001 in steroid-resistant acute graft-versus-host disease last week, we are delighted to announce that we have selected cardiovascular disease as a high-priority target area for clinical development of our high-quality mesenchymal stem cells. We have initiated the planning process for a Phase 2 trial in critical limb ischemia and look forward to providing further details in due course.”

Cynata conducted a review of the therapeutic and commercial landscape for mesenchymal stem cells (MSCs) with highly respected Boston-based consultancy ClearView Healthcare Partners. On Cynata’s behalf, ClearView reviewed over 300 potential indications and then assessed the selected candidates based on a robust and comprehensive analysis of scientific rationale, clinical development feasibility and commercial opportunity.

Cardiovascular disease, which encompasses a range of specific diseases of the heart or blood vessels, is the leading cause of premature death worldwide¹. Cynata has amassed significant data confirming the utility of its Cymerus™ MSCs in pre-clinical models of cardiovascular disease and its vascular and inflammatory complications: critical limb ischemia (CLI), diabetic ulcers and heart disease. This, combined with the ClearView analysis, has provided the Company with a sound basis to proceed with a Phase 2 clinical programme in CLI and to continue working with its partners to progress other cardiovascular disease indications. CLI patients are at substantial risk of severe disease consequences,
including limb amputation and higher mortality rates. As such, the global commercial opportunity for MSC therapies in CLI, as estimated by ClearView, has the potential to reach US$1.4 billion per year. Cynata will update the market with developments regarding its planned future activities, as appropriate.

Investor Presentation

Cynata Therapeutics offers investors exposure to the rapidly growing regenerative medicine and stem cell sector via its patented Cymerus technology, a platform able to manufacture therapeutic MSCs at a commercial scale. The new investor presentation highlights Cynata Therapeutics’ compelling investment case and provides information about the Company’s progress and its future product development pipeline.

Investment Highlights

- **Scalable, world-first technology**: Cymerus platform overcomes inherent challenges of other production methods and enables mass production of therapeutic MSCs
- **Phase 2 ready**: Excellent Phase 1 results provide validation of Cynata’s Cymerus platform; enables Cynata to progress to Phase 2 in GvHD and other indications
- **Cardiovascular disease identified as priority indication area for clinical programme**: Phase 2 trial in critical limb ischemia expected to commence in H2 2018
- **Attractive licensing-driven business model**: Fujifilm licence option for GvHD potentially worth over A$60 million plus royalties
- **Valuable market opportunity**: Estimated US$1.7 billion revenue opportunity for GvHD and CLI MSC products alone
- **Well-funded to progress clinical programme**: Pro forma cash balance of $13.5 million based on cash balance of $8.3 million at 31-Mar-18, reinforced by $5.2 million placement of shares to leading institutional investor Fidelity International in May 2018

**Ends**

**CONTACTS:**
Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, ross.macdonald@cynata.com
Daniel Paproth, Australia Media Contact, +61 (0)421 858 982, daniel.paproth@mcppartners.com.au
Annie Starr, U.S. Media Contact, 973 768 2170, astarr@6degreespr.com

**About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ utilises induced pluripotent stem cells (iPSCs) to produce a particular type of MSC precursor, called a mesenchymoangioblast (MCA). Cymerus™ provides a source of MSCs that is independent of donor limitations and an “off-the-shell” stem cell platform for therapeutic product use, with a pharmaceutical product business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics, and provides both a unique differentiator and an important competitive position.

---

1 American Heart Association
Important Information

This presentation has been prepared by Cynata Therapeutics Limited. ("Cynata" or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Cynata Therapeutics, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Cynata Therapeutics and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Cynata Therapeutics is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Cynata Therapeutics securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Cynata Therapeutics, its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Cynata Therapeutics does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

The distribution of this presentation may be restricted by law and you should observe any such restrictions.

Forward looking statements

This presentation contains certain forward looking statements that are based on the Company’s management’s beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Cynata to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the political and economic environment in which Cynata will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Cynata and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).
**Investment Summary:** a Phase II-ready biotech with a highly scalable, proprietary platform for producing commercial quantities of MSCs

- **Scalable, globally applicable technology**
  - Cymerus™ platform enables production of high quality Mesenchymal Stem Cells at scale
  - Fully patented process overcomes multiple issues with today’s on-market solutions

- **Excellent results from Phase I trial in GvHD**
  - All trial endpoints achieved to date: no adverse safety events, highly encouraging efficacy
  - GvHD programme well positioned to progress to Phase II
  - Safety data enables Cynata to move directly to Phase II in other indications

- **Clear pipeline of high-potential target areas**
  - Cardiovascular disease identified as priority indication area for expanded trial pipeline
  - Planning for Phase II programme in Critical Limb Ischemia (CLI) to commence in H2 2018
  - Compelling pre-clinical data in multiple other high-value target areas

- **Well-funded to progress clinical programme**
  - Pro-forma cash balance of $13.5m based on cash balance of $8.3m as at 31-Mar-18, reinforced by $5.2m placement of shares to leading institutional investor Fidelity International on 30-May-18

- **Attractive licensing-driven business model**
  - Fujifilm hold licence option for GvHD – will pay all costs of all further development and commercialisation plus $60m in milestone payments plus royalties if exercised
  - Licence agreements and strategic partners for other indications being explored

- **Valuable and active market**
  - Estimated $1.7bn revenue opportunity for MSC supplier for GvHD and CLI products alone
  - Over 850 clinical trials investigating the efficacy of MSCs across numerous indications
  - Multiple pharma companies active in stem-cell M&A
Cynata has the only platform in the world to produce commercial quantities of Mesenchymal Stem Cells from a single source.

Today’s on-market MSC manufacturing solution has a number of shortcomings:

- **REGULATORY ISSUES**
  - Sourcing cells from multiple donors leads to variability in the sourced cells, which is a major regulatory hurdle.

- **REDUCED EFFICACY**
  - Massive cell expansion is required to create enough cells for therapeutic use, which may result in reduced efficacy.

Surgery required to source MSCs from bone marrow:

- Multiple donors
- Complex surgery
- Cell expansion

Patented Cymerus Platform overcomes shortcomings:

- **CONSISTENT PRODUCT QUALITY**
  - Single donor overcomes regulatory concerns.

- **MAINTAINED PRODUCT EFFICACY**
  - Cymerus overcomes need for excessive expansion.

For more information on the Cymerus platform visit Cynata’s website.
MSCs are a highly potent form of stem cell attracting significant clinical interest – and in need of a scalable commercial solution.

**Mesenchymal Stem Cells (MSCs) are believed to play a vital role in repair and regeneration**

- Modulator of the immune system
- Secrete bioactive molecules and have immunosuppressive and immunoregulatory properties

---

**Over 850 clinical trials investigating the efficacy of MSCs in treating diseases have been initiated**

Number of MSC clinical trials (cumulative)

![Graph showing cumulative number of MSC clinical trials from Dec-04 to Dec-17 with an increasing trend.]

- MSCs were approved for use as a therapeutic treatment in Japan in September 2015 and Europe in March 2018

---

**Global commercial potential, with multiple target areas potentially benefiting from MSC treatment**

- Diabetes complications
- Diabetic foot ulcers
- GvHD
- Fistula
- Asthma
- Acute respiratory distress syndrome
- Brain cancer / Glioblastoma
- Osteoarthritis
- Critical limb ischemia
- Crohn’s disease
- Heart attack

---

1. www.clinicaltrials.gov (as at June 2018)
Cynata’s goal is for its patented Cymerus platform to become the preferred solution for Big Pharma to commercially produce MSCs.

**Phase I near completion, Phase II planned**
- GvHD: Fujifilm licence option

**Phase II planned**
- Critical Limb Ischemia: Licence available
- Following successful GvHD trial, a new indication will progress direct to Phase II
- Fujifilm licence option
- Licence available

**A ‘hub and spoke’ business model**
- Intention to license Cymerus across a range of target areas to maximise value

**Potential future target areas**
- Preclinical data
- Licence available
- Licence available
- Licence available

**Fujifilm licence option**
- Licence available
Trial update | Excellent results in Phase 1 GvHD clinical trial, a clear validation of Cynata’s MSCs and the Cymerus platform

Cynata is nearing completion of a successful Phase 1 clinical trial, demonstrating safety and meaningful impact on the patients’ quality of life

✓ All endpoints achieved to date
(as at Cohort B 28-day trial update, announced on 21-Jun-18)

<table>
<thead>
<tr>
<th>Safety</th>
<th>Cohort A (at 28 days)</th>
<th>Cohort A (at 100 days)</th>
<th>Cohort B (at 28 days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete response (Absence of GvHD)</td>
<td>✓ 12.5%</td>
<td>✓ 50%</td>
<td>✓ 57%</td>
</tr>
<tr>
<td>Partial response (Improvement by at least 1 GvHD grade)</td>
<td>✓ 75%</td>
<td>✓ 100%</td>
<td>✓ 86%</td>
</tr>
<tr>
<td>Overall survival¹</td>
<td>✓ 87.5%</td>
<td>✓ 87.5%</td>
<td>✓ 100%</td>
</tr>
</tbody>
</table>

1. One patient in cohort A died of pneumonia (unrelated to treatment) and one patient in cohort B withdrew from the trial on Day 22 to commence palliative care (but remained alive as at Day 28)

Excellent safety data allows multiple future indications to progress directly to Phase II
**Trial update** | Substantial improvement in GvHD grades observed with the majority of patients reporting a Complete Response

---

**Cohort A, single dose (as at 100-day readout)**

Complete Response rate of 50%

---

**Cohort B, double dose (as at 28-day readout)**

Complete Response of 57%

---

**Legend**

- GvHD grade: As at day 0
- GvHD grade: Best response
- Complete response
- Partial response
- No response

---

Note: Complete response (CR) = absence of GvHD. Partial response (PR) = improvement by at least 1 grade
**Trial update** | Response rate represents a meaningful improvement for a life-threatening, severe disease, in a $300m market opportunity\(^1\)

---

**GvHD grade scale**\(^3\)

<table>
<thead>
<tr>
<th>Grade</th>
<th>Skin grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>&gt;50% with skin peeling or blistering</td>
</tr>
<tr>
<td>3</td>
<td>&gt;50% rash or widespread skin inflammation</td>
</tr>
<tr>
<td>2</td>
<td>25-50%</td>
</tr>
<tr>
<td>1</td>
<td>&lt;25%</td>
</tr>
<tr>
<td>0</td>
<td>0%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Grade</th>
<th>Liver grade</th>
<th>Gut grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>≥ 15.0</td>
<td>&gt; 2,000ml (or severe abdominal pain with or without ileus)</td>
</tr>
<tr>
<td>3</td>
<td>6.0 – 14.9</td>
<td>1,500ml – 2,000ml</td>
</tr>
<tr>
<td>2</td>
<td>3.0 – 5.9</td>
<td>1,000ml – 1,500ml</td>
</tr>
<tr>
<td>1</td>
<td>2.0 – 2.9</td>
<td>500ml – 1,000ml (or persistent anorexia, nausea and vomiting)</td>
</tr>
<tr>
<td>0</td>
<td>&lt; 2.0</td>
<td>≤ 500ml</td>
</tr>
</tbody>
</table>

---

GvHD is a devastating disease that impacts patients who are already suffering and in need of transplants. A change in GvHD grade of only 1 has a meaningful impact on these patients’ quality of life.

---

1. Fujifilm’s estimate of the peak annual global sales opportunity (in US$); 2. Represents aggregated results of Cohort A (at 100 days) and Cohort B (at 28 days); 3. Source: www.cibmtr.org
**Trial update** | Phase 1 GvHD trial was designed to demonstrate safety of Cynata’s MSCs and support evaluation of efficacy

---

**What is GvHD?**

Graft versus host disease (GVHD) is a condition where following a transplant the donor’s immune cells in the transplant (graft) make antibodies against the patient's tissues (host) and attack vital organs. Organs most often affected include the skin, gastrointestinal (GI) tract and the liver.

---

**Overview of GvHD clinical trial**

**World’s first allogeneic iPSC-derived cell therapy clinical trial**

<table>
<thead>
<tr>
<th>Clinical trial protocol</th>
<th>CYP-GvHD-P1-01</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>~15 adults with steroid-resistant acute GvHD</td>
</tr>
<tr>
<td>Clinical sites</td>
<td>7 (UK and Australia)</td>
</tr>
</tbody>
</table>

**Endpoints**

- Safety and tolerability (primary)
- Complete/Partial Response by Day 28/Day 100
  - Complete response = absence of GvHD
  - Partial response = improvement by at least 1 grade
- Overall survival at Day 28/Day 100

**Current status**

- Cohort A – dosing completed Nov 2017, final 100 day readouts completed Feb 2018
- Cohort B – dosing completed May 2018, final 100 day readouts expected in September 2018

---

**Clinical trial design**

**Screening criteria**

- Adults with steroid resistant acute GvHD
- Life expectancy of at least 1 month
- Other conditions screened out that may impact results

**Cohort A**

May-17 – Dec-17

n=8

- 1x10⁶ cells/kg on Day 0 and Day 7
- 28 day read-out ✔
- 100 day read-out ✔

Data and Safety Monitoring Board (DSMB) assessed Cohort A 28-day data and approved commencement of Cohort B

**Cohort B**

Jan-18 – May-18

n=7³

- 2x10⁶ cells/kg on Day 0 and Day 7
- 28 day read-out ✔
- 100 day read-out

---

1. Max 1x10⁸ cells. 2. Max 2x10⁸ cells 3. One patient withdrew from trial prior to dosing; trial was intended to have 8 participants

---

**What is GvHD?**

Graft versus host disease (GVHD) is a condition where following a transplant the donor’s immune cells in the transplant (graft) make antibodies against the patient's tissues (host) and attack vital organs. Organs most often affected include the skin, gastrointestinal (GI) tract and the liver.
Cell therapy is an active market attracting big pharma M&A interest

March 2015
- Enables Fujifilm to combine technologies with Cellular Dynamics to develop new iPSC based cell therapies
- Founder of Cellular Dynamics also founded Cynata

February 2016
- Enables Astellas to establish a leading position in cell therapy
- Ocata CEO prior to acquisition was Paul Wotton, current Chairman of Cynata

January 2018¹
- Extends existing partnership between Takeda and TiGenix to develop and commercialize Cx601 (darvadstrocel)
- TiGenix was the first company to receive approval for an MSC therapy in Europe

¹ Transaction pending completion following acceptance of bid by TiGenix shareholders
Cynata is executing on a clear scientific and commercial vision and continually assesses pathways to maximise shareholder value.

**Multiple options to create shareholder value**

- **Build value in platform independently**
  *(e.g. continue running clinical trials)*

- **License / partner with big Pharma to develop specific target areas**
  *(e.g. Fujifilm’s existing option for GvHD)*

- **Asset sale**
  *(e.g. Strategic acquirer)*

---

**Fujifilm holds a licence option for development and commercialisation of Cynata’s MSCs for GvHD**

**Exercise of Fujifilm option (US$3m)**
- Fujifilm can exercise up to 90 days after completion of Phase 1 trial.
- On exercise Cynata receive upfront **US$3m** milestone payment
- Fujifilm responsible for all further development activities and costs

**Phase 2 and beyond (US$30m+ p.a.)**
- Fujifilm to pay Cynata agreed milestones *(US$60m+)* and double-digit royalties on product sales
- Fujifilm’s projections for the GvHD market suggest **>US$30m** per year in royalties for Cynata
Cynata intends to demonstrate broad global applicability of its Cymerus platform

New enhanced pipeline and clear pathway to commercialisation

- Direct path to market in Japan following Phase II
- Fujifilm holds a licence option for development and commercialisation of Cynata’s MSCs for GvHD

US$300m\(^1\)

GvHD

- Identified as high priority target area for Phase II trials
- Cynata will engage with potential partners: intention to license Cynata’s MSCs for CLI

US$1.4bn\(^2\)

Critical Limb Ischemia

Successful safety results from GvHD trial enables future indications to bypass Phase I

- Cynata will continue to develop its portfolio of target areas in pre-clinical trials with the intention of progressing selected indications to Phase II

6+ indications

Pre-clinical trials

- Cynata has identified a number of additional indications that it may choose to progress to pre-clinical testing or directly to Phase II in the future
- Significant volume of ongoing clinical research into MSC therapies (850+ clinical trials to date)

Potential target areas

Other high priority indications

1. Fujifilm’s estimate of the peak annual global sales opportunity
2. ClearView’s estimate of the peak annual global sales opportunity
ClearView were commissioned to evaluate the full landscape of MSC opportunities to identify high priority indications.

**Indication prioritisation process**

- **ClearView** identified ~20 high potential target areas with clear scientific and commercial attractiveness.

**Cardiovascular disease** selected by Cynata as highest priority indication area:
- Primary indication: **Chronic Limb Ischemia**
- Progress to clinical trials (direct to Phase II)

**Key metrics used to evaluate potential MSC indications**

| Mechanical / Scientific Attractiveness | • Expert perspectives and scientific evidence supporting rationale for use of an MSC approach |
| Clinical Development Attractiveness | • Overall burden (i.e., trial duration, trial size, recruiting hurdles)  
• Likelihood of success (endpoint feasibility) of clinical development |
| Commercial Attractiveness | • Estimated sales based on interviews with key opinion leaders on MSC therapy concepts and accounting for the future competitive landscape |
New Phase II programme in Critical Limb Ischemia | Opportunity Overview

**Critical Limb Ischemia (CLI)**
- MSC therapy for effective treatment of critical limb ischemia patients who are ineligible for revascularization, to promote angiogenesis and reduce inflammation

**Rationale for selection**
- Cymerus preclinical studies were compelling, animals treated with Cymerus MSCs experienced improved blood flow (p<0.006) and faster blood flow recovery (p<0.001) when compared to the control group treated with saline
- Development timeline is relatively rapid

**Preliminary programme design**
- Pivotal trials may last 1–2 years and require 50–100 revascularisation-ineligible patients (patients not eligible for surgery intended to restore blood flow)
- Endpoints likely to include amputation-free survival and ankle-brachial index, ulcer healing, and pain (reviewed over 6–12 months)

**Key milestones**
- Planning for Phase II programme in Chronic Limb Ischemia to commence in H2 2018

---

**Estimated market size**
- **230,000** Addressable events per year
- **~US$1.4B**\(^1\) Forecast annual global market sales

---

\(^1\) ClearView’s estimate of the peak annual global sales opportunity
Critical Limb Ischemia clinical study follows excellent results from an earlier pre-clinical study

Mice dosed with Cymerus MSCs experienced significantly improved outcomes when compared with control group

All results published in a peer reviewed journal

Animals treated with Cymerus MSCs experienced improved blood flow (p<0.006) and faster blood flow recovery (p<0.001) when compared to the control group treated with saline

Cytotherapy is a peer-reviewed medical journal covering the areas of cell biology and immunology, including cytokines, cytotherapy, and molecular therapy
Cynata is well funded to progress its enhanced clinical pipeline

<table>
<thead>
<tr>
<th></th>
<th>Pre-clinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Overview</th>
</tr>
</thead>
</table>
| **GvHD**         |              |         |          | ▪ Excellent results in Phase I GvHD clinical trial: a clear validation of Cynata’s MSCs and the Cymerus platform  
▪ Fujifilm responsible for all further development activities and costs if option exercised |
|                  | Phase II ready |        |          |          |
| **Critical Limb Ischemia (CLI)** |              |         |          | ▪ Phase I safety results for GvHD clears the path for progressing Critical Limb Ischemia directly to Phase II following encouraging preclinical results  
▪ Prioritisation work also indicated clear scientific and commercial attractiveness |
|                  | Phase II ready |        |          |          |
| **Pre-clinical pipeline (6+ indications)** |              |         |          | ▪ Continued pre-clinical work to identify and progress additional potential indications, in partnership with leading research institutions |

**Cynata is well funded:**

- $13.5m pro-forma cash balance\(^1\)
- $6.5m in-the-money stock options\(^2\)
- Cost sharing with licence partners
- R&D expenditure eligible for rebates

---

1. Cash balance at 31 March 2018 ($8.3m), adjusted for $5.2m cash from 30 May 2018 placement
2. Potential cash inflow if all in-the-money options (as at 21 June 2018) are exercised
**Key upcoming milestones**

<table>
<thead>
<tr>
<th></th>
<th>H1 CY2018</th>
<th>H2 CY2018</th>
<th>H1 CY2019</th>
<th>H2 CY2019</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GvHD</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase I clinical trials</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Critical Limb Ischemia (CLI)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Detailed trial plan announced</td>
<td></td>
<td></td>
<td>Detailed trial plan to determine timeline</td>
<td></td>
</tr>
<tr>
<td>Recruitment commences</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>All other pre-clinical</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ongoing pre-clinical programme includes studies focused on Asthma, ARDS, Heart Attack, Coronary Artery Disease, Brain Cancer / Glioblastoma, Diabetic Wounds</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Commercial</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cynata board and management seek and assess partnering and licensing opportunities on an ongoing basis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Today**
  - Cohort B 100 day read-out
  - Fujifilm licence option expires
  - If Fujifilm do not exercise their option, Cynata intends to progress to Phase 2 independently or with an alternative partner
Cynata will continue to progress pre-clinical studies with leading academic and commercial partners

<table>
<thead>
<tr>
<th>Disease target area</th>
<th>Pre-clinical trials started</th>
<th>Proof of concept completed</th>
<th>Key highlights</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma</td>
<td></td>
<td></td>
<td>Cymerus MSCs demonstrated significant beneficial effects on three key components of asthma: airway hyper-responsiveness, inflammation and airway remodelling</td>
</tr>
<tr>
<td>ARDS</td>
<td></td>
<td>✓</td>
<td>Study to commence to evaluate effectiveness of Cymerus MSCs in sheep with ARDS in association with the Prince Charles Hospital in Brisbane.</td>
</tr>
<tr>
<td>Heart attack</td>
<td></td>
<td>✓</td>
<td>Pre-clinical trials suggest Cymerus MSCs may have the potential to restore cardiac function and reduce scar size after a heart attack (US$18.2 billion market by 2019)</td>
</tr>
<tr>
<td>Brain Cancer / Glioblastoma</td>
<td></td>
<td></td>
<td>Research collaboration in genetically modified MSCs in cancer: involves modifying stem cells to target cancer</td>
</tr>
<tr>
<td>Diabetic Wounds</td>
<td></td>
<td>✓</td>
<td>Independent study by CRC for Cell Therapy Manufacturing received positive data which demonstrates the efficacy of Cymerus MSCs in a preclinical model of diabetic wounds</td>
</tr>
<tr>
<td>Coronary Artery Disease</td>
<td></td>
<td>✓</td>
<td>Research collaboration for the development of MSC therapies to treat coronary artery disease</td>
</tr>
</tbody>
</table>

Successful outcomes open many other disease targets potentially benefiting from MSCs

---

Globally experienced board and management team

**Dr Paul Wotton**
Chairman

**Dr Ross Macdonald**
Managing Director
Chief Executive Officer

**Dr Stewart Washer**
Non-Executive Director

**Dr John Chiplin**
Non-Executive Director

**Mr Peter Webs**
Non-Executive Director
Company Secretary

**Dr Kilian Kelly**
Vice President, Product Development

**Former CEO of Ocata Therapeutics (NASDAQ: OCAT) managing it through a take-over by Astellas Pharma, in a US$379m transaction**

Previous executive roles with Antares Pharma Inc. (NASDAQ: ATRS), Topigen Pharmaceuticals and SkyePharma
Founding CEO, Sigilon Therapeutics; member of the boards of Vericel Corporation and Veloxis; past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada

**Expertise running and monetising Ocata Therapeutics, acquired by Astellas**

30 years’ experience and a track record of success in pharmaceutical and biotechnology businesses
Previous senior management positions with Hatchtech, Sinclair Pharmaceuticals, Connetics Corporation (Palo Alto, CA), and Stiefel Laboratories, the largest independent dermatology company in the world and acquired by GSK in 2009 for £2.25b

**Deep experience growing companies as CEO and on the Board**

30 years’ experience and a track record of success in pharmaceutical and biotechnology businesses
Previous senior management positions with Hatchtech, Sinclair Pharmaceuticals, Connetics Corporation (Palo Alto, CA), and Stiefel Laboratories, the largest independent dermatology company in the world and acquired by GSK in 2009 for £2.25b

**Overseen and managed a broad range of life sciences transactions**

25+ years company secretarial and management experience

**Academic and commercial excellence, extensive relevant management experience**

**+25 years’ company secretarial experience**

Managing Director of Platinum Corporate Secretariat Pty Ltd, a company specialising in providing company secretarial, corporate governance and corporate advisory services

**Significant international experience in the life science and technology industries**

Recent transactions include US stem cell company Medistem (acquired by Intrexon), Arana (acquired by Cephalon), and Domantis (acquired by GSK)

Was head of the $300M ITI Life Sciences investment fund in the UK and his own investment vehicle, Newstar Ventures

**Track record of success in pharmaceutical and biotechnology businesses**

30 years’ experience and a track record of success in pharmaceutical and biotechnology businesses
Previous senior management positions with Hatchtech, Sinclair Pharmaceuticals, Connetics Corporation (Palo Alto, CA), and Stiefel Laboratories, the largest independent dermatology company in the world and acquired by GSK in 2009 for £2.25b

**Deep experience growing companies as CEO and on the Board**

30 years’ experience and a track record of success in pharmaceutical and biotechnology businesses
Previous senior management positions with Hatchtech, Sinclair Pharmaceuticals, Connetics Corporation (Palo Alto, CA), and Stiefel Laboratories, the largest independent dermatology company in the world and acquired by GSK in 2009 for £2.25b

**Significant international experience in the life science and technology industries**

Recent transactions include US stem cell company Medistem (acquired by Intrexon), Arana (acquired by Cephalon), and Domantis (acquired by GSK)

Was head of the $300M ITI Life Sciences investment fund in the UK and his own investment vehicle, Newstar Ventures

**Overseen and managed a broad range of life sciences transactions**

25+ years company secretarial and management experience

**Academic and commercial excellence, extensive relevant management experience**

**30 years’ experience and a track record of success in pharmaceutical and biotechnology businesses**

Previous senior management positions with Hatchtech, Sinclair Pharmaceuticals, Connetics Corporation (Palo Alto, CA), and Stiefel Laboratories, the largest independent dermatology company in the world and acquired by GSK in 2009 for £2.25b

**Deep experience growing companies as CEO and on the Board**

30 years’ experience and a track record of success in pharmaceutical and biotechnology businesses
Previous senior management positions with Hatchtech, Sinclair Pharmaceuticals, Connetics Corporation (Palo Alto, CA), and Stiefel Laboratories, the largest independent dermatology company in the world and acquired by GSK in 2009 for £2.25b

**Significant international experience in the life science and technology industries**

Recent transactions include US stem cell company Medistem (acquired by Intrexon), Arana (acquired by Cephalon), and Domantis (acquired by GSK)

Was head of the $300M ITI Life Sciences investment fund in the UK and his own investment vehicle, Newstar Ventures

**Overseen and managed a broad range of life sciences transactions**

25+ years company secretarial and management experience

**Academic and commercial excellence, extensive relevant management experience**

**Significant international experience in the life science and technology industries**

Recent transactions include US stem cell company Medistem (acquired by Intrexon), Arana (acquired by Cephalon), and Domantis (acquired by GSK)

Was head of the $300M ITI Life Sciences investment fund in the UK and his own investment vehicle, Newstar Ventures

**Overseen and managed a broad range of life sciences transactions**

25+ years company secretarial and management experience

**Academic and commercial excellence, extensive relevant management experience**
Investment Highlights

- **Scalable, world-first technology:** Cymerus platform overcomes inherent challenges of other production methods and enables mass-production of therapeutic MSCs

- **Phase II ready:** Excellent Phase I results provide validation of Cynata’s Cymerus platform; Cynata well positioned to progress to Phase II in GvHD and other indications

- **Cardiovascular disease identified as priority indication area for clinical programme:** Planning for Phase II in Critical Limb Ischemia to commence in H2 2018

- **Attractive licensing-driven business model:** Fujifilm licence option for GvHD worth over US$60m plus royalties

- **Valuable market opportunity:** Estimated US$1.7bn revenue opportunity for MSC supplier for GvHD and CLI products alone

- **Well-funded to progress clinical programme:** Pro forma cash balance of $13.5m
## Appendix | Key recent newsflow: last 6 months

<table>
<thead>
<tr>
<th>Release date</th>
<th>Announcement</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GvHD</strong></td>
<td></td>
</tr>
<tr>
<td>21-Jun-18</td>
<td>Positive 28-day data from Cohort B</td>
</tr>
<tr>
<td>12-Jun-18</td>
<td>Positive 6-month data from Cohort A</td>
</tr>
<tr>
<td>24-May-18</td>
<td>Enrolment completed in Cynata’s Phase 1 Clinical Trial</td>
</tr>
<tr>
<td>28-Mar-18</td>
<td>FDA Grants Orphan Drug Designation to Cynata for CYP-001</td>
</tr>
<tr>
<td>27-Feb-18</td>
<td>Excellent 100-day data from Cohort A</td>
</tr>
<tr>
<td>24-Jan-18</td>
<td>Cynata treats first patient in Cohort B</td>
</tr>
<tr>
<td>22-Jan-18</td>
<td>Encouraging early data – DSMB recommendation to progress to Cohort B</td>
</tr>
<tr>
<td><strong>Pre-clinical / other</strong></td>
<td></td>
</tr>
<tr>
<td>18-Jun-18</td>
<td>Research Collaboration with UNSW for Coronary Artery Disease</td>
</tr>
<tr>
<td>31-May-18</td>
<td>Cynata’s MSCs Effective in Model of Diabetic Wounds</td>
</tr>
<tr>
<td>7-May-18</td>
<td>Notice of Allowance from EPO for Cymerus Technology Patent Application</td>
</tr>
<tr>
<td>20-Apr-18</td>
<td>CYP completes patent application related to CAR-T Therapy</td>
</tr>
<tr>
<td>11-Apr-18</td>
<td>Further US patent granted for Cynata’s Cymerus Technology</td>
</tr>
<tr>
<td>5-Feb-18</td>
<td>Cynata engineered MSC study interim data review reveals promising results</td>
</tr>
<tr>
<td><strong>Commercial</strong></td>
<td></td>
</tr>
<tr>
<td>30-May-18</td>
<td>$5.2m placement of shares to Fidelity International</td>
</tr>
<tr>
<td>23-Jan-18</td>
<td>Cynata &amp; Cellularity Inc Execute MOU</td>
</tr>
</tbody>
</table>
Company profile

Cynata Therapeutics is an Australian stock exchange listed clinical-stage biotechnology company developing disruptive regenerative medicines.

Financial information

<table>
<thead>
<tr>
<th>Share price (21-June-18)</th>
<th>A$1.37</th>
</tr>
</thead>
<tbody>
<tr>
<td>52 week low / high</td>
<td>A$0.54 / A$1.54</td>
</tr>
<tr>
<td>Shares on issue¹</td>
<td>95.1m</td>
</tr>
<tr>
<td><strong>Market capitalisation</strong></td>
<td>A$129.8m</td>
</tr>
<tr>
<td>Pro-forma Cash (as at 31-March-18)²</td>
<td>A$13.5m</td>
</tr>
<tr>
<td>Debt (as at 31-March-18)</td>
<td>-</td>
</tr>
<tr>
<td><strong>Enterprise value</strong></td>
<td>A$116.3m</td>
</tr>
</tbody>
</table>

Source: IRESS
Notes:
1. Excludes 11.2m unquoted options with exercise prices ranging from $0.40 to $1.50 and expiry dates between 27-Sep-2018 and 4-Aug-2020 (1m subject to vesting conditions), and 750k unlisted incentive options with exercise price $0.49 and expiring 16 December 2018
2. Pro-forma cash calculated as cash balance at 31-Mar-2018 ($8.3m), adjusted for $5.2m cash from 30-May-2018 placement
3. Represents shareholding if all options held by the Board and Management (total of 8.55m) are exercised

Share price performance (last 6 months, A$)

Top shareholders

<table>
<thead>
<tr>
<th>Shareholder</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fidelity International</strong></td>
<td>10.0%</td>
</tr>
<tr>
<td>Fujifilm Corporation</td>
<td>8.5%</td>
</tr>
<tr>
<td>Board and Management</td>
<td>0.6%</td>
</tr>
<tr>
<td>**Board and Management (fully diluted)**³</td>
<td>8.8%</td>
</tr>
</tbody>
</table>
Thank you for your attention

Cynata Therapeutics Limited
Level 3
62 Lygon Street
Carlton
Victoria 3053
Australia

Contact details:

ross.macdonald@cynata.com
+61 (0) 412 119343
www.cynata.com